PRS50 Defining Type 2 Asthma and Patients Eligible to Dupilumab in Italy: A Biomarker-Based AnalysisG.W. Canonica,F. Blasi,N. Crimi,P. Paggiaro,A. Papi,F. Fanelli, A. Stassaldi, A. Serra,G. FurneriValue in Health(2020)引用 11|浏览0暂无评分关键词Type 2 asthma,Dupilumab,Biomarkers,ItalyAI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要